Thursday, December 8, 2022

Dantari Gets $47M For Tumor Medicine Effort

Thousand Oaks-based Dantari has raised $47M in its Series A funding, saying that it has launched a new, clinical-stage biotechnology company developing targeted therapeutics for the treatment of cancers and other diseases. The company said the funding was led by Westlake Village BioPartners and included participation from Corner Ventures, Alexandria Venture Investments, and Caltech. Dantari has appointed Richard A. Markus, M.D., Ph.D., as president and chief executive officer (CEO), and also added a board of directors headed by chair Sean Harper, M.D., a co-founding managing director at Westlake. The company's lead clinical investigational product is DAN-222, a novel HDC chemotherapeutic agent with a topoisomerase 1 inhibitor (topo1) payload, which the company said is being evaluated in a Phase 1/2 clinical trial for the treatment of metastatic human epidermal growth factor receptor (HER) 2-negative breast cancer.